Document is current
Any future updates will be listed below
-
Authors
Escoto, Angelica https://orcid.org/0000-0003-0214-2718
Hecksel, Ryan https://orcid.org/0000-0003-4189-6950
Parkinson, Chance
Crane, Sara
Atwell, Benjamin
King, Shyanne https://orcid.org/0000-0001-9345-0622
Ortiz Chavez, Daniela
Jannuzi, Alison
Sands, Barbara
Bitler, Benjamin G. https://orcid.org/0000-0002-5809-5271
Fehniger, Todd A.
Paek, Andrew L.
Padi, Megha
Schroeder, Joyce https://orcid.org/0000-0003-1277-5172
- License Information
-
More Information
Article History
Received: 30 April 2024
Revised: 23 October 2024
Accepted: 28 October 2024
First Online: 9 November 2024
Competing interests
: TAF has licensed patents, equity, consulting, and potential royalty interests in Wugen; equity interests in Indapta Therapeutics and Orca Bio; and serves as a consultant for Affimed, AI Proteins, and Smart Immune; and has research funding from HCW biologics, Wugen, and Affimed.
: All methods were performed in accordance with the relevant guidelines and regulations. No human subjects were involved in this research. All animal studies were approved by the University of Arizona Institutional Animal Care and Use Committee, protocol approval #18-427.
